Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

EHA 2025

Multiple Myeloma (MM)

GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM

Multiple Myeloma (MM)

Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

Blood Cancer J

Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A

doi: 10.1038/s41408-025-01253-5

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

ASH 2024

Multiple Myeloma (MM)

Isatuximab plus RVd yields deep MRD negativity and PFS benefit in transplant-eligible patients with NDMM

EHA 2025

Multiple Myeloma (MM)

RedirecTT-1: Deep and durable responses with talquetamab plus teclistamab in RRMM patients with extramedullary disease

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

Multiple Myeloma (MM)

Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study

Leuk Lymphoma

Knauf W, Uhlig J, von der Heyde E, Losem C, Ammon A, Nusch A, Schlag R, Schulz H, Janssen J, Welslau M, Wilop S, Vannier C, Siebenbach HU, Serrer L, Schuch A, Woerner SM, Engelhardt M, Potthoff K

doi: 10.1080/10428194.2024.2436034

ESMO 2024

Genitourinary Cancer

Oncology · Hematology

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

Related content

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM

Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Isatuximab plus RVd yields deep MRD negativity and PFS benefit in transplant-eligible patients with NDMM

RedirecTT-1: Deep and durable responses with talquetamab plus teclistamab in RRMM patients with extramedullary disease

Results of TRODELVY® real-world data

Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study

223Ra followed by 177Lu-PSMA was clinically feasible in heavily pretreated patients with mCRPC in clinical practice

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Results of TRODELVY^® real-world data

²²³Ra followed by ¹⁷⁷Lu-PSMA was clinically feasible in heavily pretreated patients with mCRPC in clinical practice